டிமிட்ரியோஸ் தேவதூதர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from டிமிட்ரியோஸ் தேவதூதர்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In டிமிட்ரியோஸ் தேவதூதர்கள் Today - Breaking & Trending Today

Locanabio Announces Upcoming Preclinical Data Presentations at American Society of Gene and Cell Therapy Annual Meeting


Locanabio Announces Upcoming Preclinical Data Presentations at American Society of Gene and Cell Therapy Annual Meeting
News provided by
Share this article
Share this article
SAN DIEGO, May 5, 2021 /PRNewswire/  Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, today announced that new data from its preclinical research will be highlighted in oral and poster presentations at the 24th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting, taking place virtually from May 11-14, 2021. The presentations include results from a preclinical
in vivo study showing a novel PUF RNA-binding protein system delivered via an adeno-associated virus serotype 9 (AAV9) vector is safe and effective in eliminating toxic CUG repeats in a mouse model of myotonic dystrophy type 1 (DM1). Data also provide insights on the potential of a unique ....

United States , Haydee Gutierrez , Dimitrios Zisoulis , Nandini Narayan , Scott Davis , Ranjan Batra , Shawn Lee , Greg Nachtrab , Dan Gibbs , Alistair Wilson , Dimitrios Angelis , Daniela Martino Roth , Claire Geddes , Daniela Roth , American Society Of Gene , Locanabio Inc , Berry Company , Annual American Society , Cell Therapy , System Corrects Molecular , Functional Defects , Myotonic Dystrophy Type , Aaron Berlin , Targeting Gene Therapy Approach , Syndrome Type , Rea Lardelli ,

Sparta Biomedical Receives FDA Breakthrough Device Designation for SBM-01 Biomimetic Implant


Share this article
Share this article
DURHAM, N.C., March 17, 2021 /PRNewswire/ Sparta Biomedical Inc., a developer of orthopedic solutions, today announced that its SBM-01 Biomimetic Implant has been granted a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). SBM-01 is intended to replace damaged knee cartilage in patients having single or multiple chondral or osteochondral defects in the knee.
The Breakthrough Device Program is designed to accelerate patient access to promising technologies that have the potential to provide more effective treatments for debilitating conditions. The Program provides patients and health care providers timely access to these medical devices by assisting sponsors in their development, assessment, and review, consistent with the FDA s mission to protect and promote public health. ....

Dimitrios Angelis , Adam Yanke , Breakthrough Device Program , Prnewswire Sparta Biomedical Inc , Drug Administration , Department Of Orthopedics , Sparta Biopharma Inc , Rush University Medical Center , Cartilage Restoration Center , Sparta Biomedical Inc , Dushyanth Surakanti Co , Biomedical Inc , Breakthrough Device Designation , Dushyanth Surakanti Co Founder , Assistant Director , Assistant Professor , Sparta Biomedical , Sparta Biopharma , டிமிட்ரியோஸ் தேவதூதர்கள் , ஆடம் யாங்கே , திருப்புமுனை சாதனம் ப்ரோக்ர்யாம் , துறை ஆஃப் எலும்பியல் , அவசரம் பல்கலைக்கழகம் மருத்துவ மையம் , குருத்தெலும்பு மறுசீரமைப்பு மையம் , ஸ்பார்டா உயிர் மருத்துவ இன்க் , உயிர் மருத்துவ இன்க் ,

Sparta Biopharma Announces US Commercial Availability of BioEnthesis™ for Rotator Cuff Repair


Sparta Biopharma Announces US Commercial Availability of BioEnthesis™ for Rotator Cuff Repair
News provided by
Share this article
Share this article
DURHAM, N.C. and MADISON, N.J., March 9, 2021 /PRNewswire/  Sparta Biopharma, Inc., a privately-held company, developing osteobiologics for sports medicine announces the availability of BioEnthesis
TM, the first-of-its-kind allograft that has both mineralized and demineralized layers which provide the requisite properties for healing and repair within the rotator cuff.  According to the Healthcare Cost and Utilization Project, there are more than 4.5 million physician visits per year for rotator cuff pain and dysfunction.
Osteobiologics have been used successfully over the last several decades. These allografts have facilitated the formation of functional bone tissue and the healing of bone. In that time, hundreds of allograft compositions and forms have served patients across multiple orthopedic ailments ....

Dimitrios Angelis , Adam Yanke , Dushyanth Surakanti , Sparta Biopharma Inc , Sparta Biopharma , Healthcare Cost , Utilization Project , Scientific Advisory Board , Assistant Professor , Midwest Orthopedics , Good Tissue , Health Care Amp Hospitals , Medical Equipment , Medical Pharmaceuticals , General Sports , டிமிட்ரியோஸ் தேவதூதர்கள் , ஆடம் யாங்கே , சுகாதாரம் செலவு , பயன்பாடு ப்ராஜெக்ட் , உதவியாளர் ப்ரொஃபெஸர் , மிட்வெஸ்ட் எலும்பியல் , நல்ல திசு , ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் , மருத்துவ உபகரணங்கள் , மருத்துவ மருந்துகள் , ஜநரல் விளையாட்டு ,